Overview

Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk)
Status:
Terminated
Trial end date:
2020-04-30
Target enrollment:
Participant gender:

Summary
Hematopoietic stem cell transplantation in patients with newly diagnosed AML ≤60 years of age in intermediate risk, after first complete response in comparison to standard consolidation chemotherapy
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital Carl Gustav Carus
Collaborator:
German Research Foundation
Treatments:
Cytarabine